Identification of a novel mutation in the EXT1 gene from a patient with multiple osteochondromas by exome sequencing

Hong,Guolin; Guo,Xiaoyan; Yan,Wei; Li,Qianqian; Zhao,Hailing; Ma,Ping; Hu,Xiao

doi:10.3892/mmr.2016.6086

Identification of a novel mutation in the EXT1 gene from a patient with multiple osteochondromas by exome sequencing

Authors:
- Guolin Hong
- Xiaoyan Guo
- Wei Yan
- Qianqian Li
- Hailing Zhao
- Ping Ma
- Xiao Hu
View Affiliations

Affiliations: Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, P.R. China, Department of Laboratory Medicine, The Fuzhou Second Affiliated Hospital of Xiamen University, Fuzhou, Fujian 350007, P.R. China, Department of Bone Tumors, The Fuzhou Second Affiliated Hospital of Xiamen University, Fuzhou, Fujian 350007, P.R. China, Medical College, Xiamen University, Xiamen, Fujian 361102, P.R. China, Shenzhen Huada Gene Research Institute, Shenzhen, Fujian 518083, P.R. China
Published online on: December 29, 2016 https://doi.org/10.3892/mmr.2016.6086
Pages: 657-664
Copyright: © Hong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple osteochondromas (MO) is an autosomal skeletal disease with an elusive molecular mechanism. To further elucidate the genetic mechanism of the disease a three‑generation Chinese family with MO was observed and researched, and a novel frameshift mutation (c.335_336insA) in the exotosin 1 (EXT1) gene of one patient with MO was observed through exome sequencing. This was further validated by Sanger sequencing and comparison with 200 unrelated healthy controls. Immunohistochemistry and multiple sequence alignment were performed to determine the pathogenicity of the candidate mutation. Multiple sequence alignment suggested that codon 335 and 336 in the EXT1 gene were highly conserved regions in vertebrates. Immunohistochemistry revealed that EXT1 protein expression levels were decreased in a patient with MO and this mutation compared with a patient with MO who had no EXT1 mutation. Owing to the appearance of c.335_336insA in exon 1 of EXT1, a premature stop codon was introduced, resulting in truncated EXT1. As a result integrated and functional EXT1 was reduced. EXT1 is involved in the biosynthesis of heparan sulfate (HS), an essential molecule, and its dysfunction may lead to MO. The novel mutation of c.335_336insA in the EXT1 gene reported in the present study has enlarged the causal mutation spectrum of MO, and may assist genetic counseling and prenatal diagnosis of MO.

View Figures

View References

1	Schmale GA, Conrad EU III and Raskind WH: The natural history of hereditary multiple exostoses. J Bone Joint Surg Am. 76:986–992. 1994. View Article : Google Scholar : PubMed/NCBI
2	Jennes I, Pedrini E, Zuntini M, Mordenti M, Balkassmi S, Asteggiano CG, Casey B, Bakker B, Sangiorgi L and Wuyts W: Multiple osteochondromas: Mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat. 30:1620–1627. 2009. View Article : Google Scholar : PubMed/NCBI
3	Tian C, Yan R, Wen S, Li X, Li T, Cai Z, Du H and Chen H: A splice mutation and mRNA decay of EXT2 provoke hereditary multiple exostoses. PLoS One. 9:e948482014. View Article : Google Scholar : PubMed/NCBI
4	Stieber JR and Dormans JP: Manifestations of hereditary multiple exostoses. J Am Acad Orthop Surg. 13:110–20. 2005. View Article : Google Scholar : PubMed/NCBI
5	Jamsheer A, Socha M, Sowińska-Seidler A, Telega K, Trzeciak T and Latos-Bieleńska A: Mutational screening of EXT1 and EXT2 genes in Polish patients with hereditary multiple exostoses. J Appl Genet. 55:183–188. 2014. View Article : Google Scholar : PubMed/NCBI
6	Vanita V, Sperling K, Sandhu HS, Sandhu PS and Singh JR: Novel EXT1 and EXT2 mutations in hereditary multiple exostoses families of Indian origin. Genet Test Mol Biomarkers. 13:43–49. 2009. View Article : Google Scholar : PubMed/NCBI
7	Wu Y, Xing X, Xu S, Ma H, Cao L, Wang S and Luo Y: Novel and recurrent mutations in the EXT1 and EXT2 genes in Chinese kindreds with multiple osteochondromas. J Orthop Res. 31:1492–1499. 2013. View Article : Google Scholar : PubMed/NCBI
8	Jones KB, Datar M, Ravichandran S, Jin H, Jurrus E, Whitaker R and Capecchi MR: Toward an understanding of the short bone phenotype associated with multiple osteochondromas. J Orthop Res. 31:651–657. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wuyts W and Van Hul W: Molecular basis of multiple exostoses: Mutations in the EXT1 and EXT2 genes. Hum Mutat. 15:220–227. 2000. View Article : Google Scholar : PubMed/NCBI
10	Wuyts W, Radersma R, Storm K and Vits L: An optimized DHPLC protocol for molecular testing of the EXT1 and EXT2 genes in hereditary multiple osteochondromas. Clin Genet. 68:542–547. 2005. View Article : Google Scholar : PubMed/NCBI
11	Lonie L, Porter DE, Fraser M, Cole T, Wise C, Yates L, Wakeling E, Blair E, Morava E, Monaco AP and Ragoussis J: Determination of the mutation spectrum of the EXT1/EXT2 genes in British Caucasian patients with multiple osteochondromas, and exclusion of six candidate genes in EXT negative cases. Hum Mutat. 27:11602006. View Article : Google Scholar : PubMed/NCBI
12	McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP and Tufaro F: The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet. 19:158–161. 1998. View Article : Google Scholar : PubMed/NCBI
13	Zak BM, Crawford BE and Esko JD: Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta. 1573:346–355. 2002. View Article : Google Scholar : PubMed/NCBI
14	Ahn J, Lüdecke HJ, Lindow S, Horton WA, Lee B, Wagner MJ, Horsthemke B and Wells DE: Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet. 11:137–143. 1995. View Article : Google Scholar : PubMed/NCBI
15	Stickens D, Clines G, Burbee D, Ramos P, Thomas S, Hogue D, Hecht JT, Lovett M and Evans GA: The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet. 14:25–32. 1996. View Article : Google Scholar : PubMed/NCBI
16	Le Merrer M, Legeai-Mallet L, Jeannin PM, Horsthemke B, Schinzel A, Plauchu H, Toutain A, Achard F, Munnich A and Maroteaux P: A gene for hereditary multiple exostoses maps to chromosome 19p. Hum Mol Genet. 3:717–722. 1994. View Article : Google Scholar : PubMed/NCBI
17	Trebicz-Geffen M, Robinson D, Evron Z, Glaser T, Fridkin M, Kollander Y, Vlodavsky I, Ilan N, Law KF, Cheah KS, et al: The molecular and cellular basis of exostosis formation in hereditary multiple exostoses. Int J Exp Pathol. 89:321–331. 2008. View Article : Google Scholar : PubMed/NCBI
18	Pedrini E, De Luca A, Valente EM, Maini V, Capponcelli S, Mordenti M, Mingarelli R, Sangiorgi L and Dallapiccola B: Novel EXT1 and EXT2 mutations identified by DHPLC in Italian patients with multiple osteochondromas. Hum Mutat. 26:2802005. View Article : Google Scholar : PubMed/NCBI
19	Sarrión P, Sangorrin A, Urreizti R, Delgado A, Artuch R, Martorell L, Armstrong J, Anton J, Torner F, Vilaseca MA, et al: Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas. Sci Rep. 3:13462013. View Article : Google Scholar : PubMed/NCBI
20	Huang XF, Xiang P, Chen J, Xing DJ, Huang N, Min Q, Gu F, Tong Y, Pang CP, Qu J and Jin ZB: Targeted exome sequencing identified novel USH2A mutations in Usher syndrome families. PLoS One. 8:e638322013. View Article : Google Scholar : PubMed/NCBI
21	Liu H, Wu S, Duan L, Zhu W, Zhang S, Hu X, Jia W, Yang G, Liu C, Li W, et al: Identification of a novel EXT1 mutation in patients with hereditary multiple exostosis by exome sequencing. Oncol Rep. 33:547–552. 2015.PubMed/NCBI
22	Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, et al: Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 3:92ra662011. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Glusman G, Caballero J, Mauldin DE, Hood L and Roach JC: Kaviar: An accessible system for testing SNV novelty. Bioinformatics. 27:3216–3217. 2011. View Article : Google Scholar : PubMed/NCBI
25	Porter DE, Lonie L, Fraser M, Dobson-Stone C, Porter JR, Monaco AP and Simpson AH: Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study. J Bone Joint Surg Br. 86:1041–1046. 2004. View Article : Google Scholar : PubMed/NCBI
26	Francannet C, Cohen-Tanugi A, Le Merrer M, Munnich A, Bonaventure J and Legeai-Mallet L: Genotype-phenotype correlation in hereditary multiple exostoses. J Med Genet. 38:430–434. 2001. View Article : Google Scholar : PubMed/NCBI
27	Alvarez CM, De Vera MA, Heslip TR and Casey B: Evaluation of the anatomic burden of patients with hereditary multiple exostoses. Clin Orthop Relat Res. 462:73–79. 2007. View Article : Google Scholar : PubMed/NCBI
28	McCormick C, Duncan G, Goutsos KT and Tufaro F: The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA. 97:668–4073. 2000. View Article : Google Scholar : PubMed/NCBI
29	Esko JD and Lindahl U: Molecular diversity of heparan sulfate. J Clin Invest. 108:169–173. 2001. View Article : Google Scholar : PubMed/NCBI
30	Jones KB, Pacifici M and Hilton MJ: Multiple hereditary exostoses (MHE): Elucidating the pathogenesis of a rare skeletal disorder through interdisciplinary research. Connect Tissue Res. 55:80–88. 2014. View Article : Google Scholar : PubMed/NCBI
31	Koziel L, Kunath M, Kelly OG and Vortkamp A: Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell. 6:801–813. 2004. View Article : Google Scholar : PubMed/NCBI
32	Anower-E-Khuda MF, Matsumoto K, Habuchi H, Morita H, Yokochi T, Shimizu K and Kimata K: Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application. Glycobiology. 23:865–876. 2013. View Article : Google Scholar : PubMed/NCBI
33	Jochmann K, Bachvarova V and Vortkamp A: Reprint of: Heparan sulfate as a regulator of endochondral ossification and osteochondroma development. Matrix Biol. 35:239–247. 2014. View Article : Google Scholar : PubMed/NCBI
34	Gerards M, van den Bosch B, Calis C, Schoonderwoerd K, van Engelen K, Tijssen M, De Coo R, van der Kooi A and Smeets H: Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy. Mitochondrion. 10:510–515. 2010. View Article : Google Scholar : PubMed/NCBI
35	Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, Mancias P, Butler IJ, Wilkinson MF, Wegner M and Lupski JR: Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat Genet. 36:361–369. 2004. View Article : Google Scholar : PubMed/NCBI
36	Zhang F, Liang J, Guo X, Zhang Y, Wen Y, Li Q, Zhang Z, Ma W, Dai L, Liu X, et al: Exome sequencing and functional analysis identifies a novel mutation in EXT1 gene that causes multiple osteochondromas. PLoS One. 8:e723162013. View Article : Google Scholar : PubMed/NCBI